Deucravacitinib onset of action and maintenance of response in Phase 3 plaque psoriasis trials
J Dermatolog Treat 2024;35:2371045 doi: 10.1080/09546634.2024.2371045
The analysis of the POETYK PSO-1 and POETYK PSO-2 clinical trials showed that deucravacitinib 6mg QD displayed efficacy as early as 1 week, and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.
In both clinical trials, patients with moderate to severe stable plaque psoriasis were randomised 1:2:1 to placebo, deucravacitinib or apremilast. The study didn’t focus on apremilast as the focus was to analyse the speed of onset and maintenance of response with deucravacitinib in the study population. At Week 16, patients randomised to placebo in both trials crossed over to deucravacitinib 6 mg. The coprimary endpoints were PASI 75 and a static Physician Global Assessment score of 0/1 at Week 16.
Keywords:
